MeiraGTx (MGTX) Surges 14.9%: Is This an Indication of Further Gains? — Oct 16th, 2024

MeiraGTx Holdings PLC (MGTX) shares ended the last trading session 14.9% higher at $5.33. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 10.5% gain over the past four weeks. The stock price rall...

Investing in Merus (NASDAQ:MRUS) five years ago would have delivered you a 227% gain — Oct 17th, 2024

When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose your money. But on the bright side, you can make far more than 100% on a really good stock. One great example is Merus N.V. (NASDAQ:MRUS) which saw its share price drive 227%...

MeiraGTx (MGTX) Surges 14.9%: Is This an Indication of Further Gains? — Oct 16th, 2024

MeiraGTx Holdings PLC (MGTX) shares ended the last trading session 14.9% higher at $5.33. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 10.5% gain over the past four weeks. The stock price rall...

Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC — Sep 30th, 2024

Merus N.V. UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today anno...

MeiraGTx (MGTX) Surges 14.9%: Is This an Indication of Further Gains? — Oct 16th, 2024

MeiraGTx Holdings PLC (MGTX) shares ended the last trading session 14.9% higher at $5.33. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 10.5% gain over the past four weeks. The stock price rall...

MeiraGTx (MGTX) Surges 14.9%: Is This an Indication of Further Gains? — Oct 16th, 2024

MeiraGTx Holdings PLC (MGTX) shares ended the last trading session 14.9% higher at $5.33. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 10.5% gain over the past four weeks. The stock price rall...

Investing in Merus (NASDAQ:MRUS) five years ago would have delivered you a 227% gain — Oct 17th, 2024

When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose your money. But on the bright side, you can make far more than 100% on a really good stock. One great example is Merus N.V. (NASDAQ:MRUS) which saw its share price drive 227%...

Investing in Merus (NASDAQ:MRUS) five years ago would have delivered you a 227% gain — Oct 17th, 2024

When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose your money. But on the bright side, you can make far more than 100% on a really good stock. One great example is Merus N.V. (NASDAQ:MRUS) which saw its share price drive 227%...

MeiraGTx (MGTX) Surges 14.9%: Is This an Indication of Further Gains? — Oct 16th, 2024

MeiraGTx Holdings PLC (MGTX) shares ended the last trading session 14.9% higher at $5.33. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 10.5% gain over the past four weeks. The stock price rall...

Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC — Sep 30th, 2024

Merus N.V. UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today anno...

Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC — Sep 30th, 2024

Merus N.V. UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today anno...

Investing in Merus (NASDAQ:MRUS) five years ago would have delivered you a 227% gain — Oct 17th, 2024

When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose your money. But on the bright side, you can make far more than 100% on a really good stock. One great example is Merus N.V. (NASDAQ:MRUS) which saw its share price drive 227%...

Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC — Sep 30th, 2024

Merus N.V. UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today anno...

Investing in Merus (NASDAQ:MRUS) five years ago would have delivered you a 227% gain — Oct 17th, 2024

When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose your money. But on the bright side, you can make far more than 100% on a really good stock. One great example is Merus N.V. (NASDAQ:MRUS) which saw its share price drive 227%...

Investing in Merus (NASDAQ:MRUS) five years ago would have delivered you a 227% gain — Oct 17th, 2024

When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose your money. But on the bright side, you can make far more than 100% on a really good stock. One great example is Merus N.V. (NASDAQ:MRUS) which saw its share price drive 227%...

Investing in Merus (NASDAQ:MRUS) five years ago would have delivered you a 227% gain — Oct 17th, 2024

When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose your money. But on the bright side, you can make far more than 100% on a really good stock. One great example is Merus N.V. (NASDAQ:MRUS) which saw its share price drive 227%...

Investing in Merus (NASDAQ:MRUS) five years ago would have delivered you a 227% gain — Oct 17th, 2024

When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose your money. But on the bright side, you can make far more than 100% on a really good stock. One great example is Merus N.V. (NASDAQ:MRUS) which saw its share price drive 227%...

MeiraGTx (MGTX) Surges 14.9%: Is This an Indication of Further Gains? — Oct 16th, 2024

MeiraGTx Holdings PLC (MGTX) shares ended the last trading session 14.9% higher at $5.33. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 10.5% gain over the past four weeks. The stock price rall...

Investing in Merus (NASDAQ:MRUS) five years ago would have delivered you a 227% gain — Oct 17th, 2024

When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose your money. But on the bright side, you can make far more than 100% on a really good stock. One great example is Merus N.V. (NASDAQ:MRUS) which saw its share price drive 227%...

MeiraGTx (MGTX) Surges 14.9%: Is This an Indication of Further Gains? — Oct 16th, 2024

MeiraGTx Holdings PLC (MGTX) shares ended the last trading session 14.9% higher at $5.33. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 10.5% gain over the past four weeks. The stock price rall...

Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC — Sep 30th, 2024

Merus N.V. UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today anno...

Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC — Sep 30th, 2024

Merus N.V. UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today anno...

MeiraGTx (MGTX) Surges 14.9%: Is This an Indication of Further Gains? — Oct 16th, 2024

MeiraGTx Holdings PLC (MGTX) shares ended the last trading session 14.9% higher at $5.33. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 10.5% gain over the past four weeks. The stock price rall...

Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC — Sep 30th, 2024

Merus N.V. UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today anno...